Author:
Greillier Laurent,Monjanel-Mouterde Suzanne,Fraticelli Anne,Devictor-Pierre Bénédicte,Bouvenot Julien,Coltel Nicolas,Lamarche Gérald,Astoul Philippe
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference17 articles.
1. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis;Berghmans;Lung Cancer,2002
2. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes;Shih;Cancer Res,1997
3. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003
4. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation;Rinaldi;Cancer Chemother Pharmacol,1999
5. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate;McDonald;Clin Cancer Res,1998
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献